There is also evidence that RGS5 can act as a physiological regulator of calcium sensing in the parathyroid gland as a inhibitor of calcium-sensing receptor (CaSR) signalling [30], and a study of patients with the stage 3–4 CKD determined that the lower serum calcium is associated with the higher risk of renal replacement therapy and rapid renal function progression [31]. This evidence concerns the gene CASR and chronic kidney disease.